Innovaccer Launches ‘Innovaccer Gravity
SAN FRANCISCO--(BUSINESS WIRE)--Innovaccer Inc., a leading healthcare AI company, today announced the launch of 'Innovaccer Gravity ™ ', its Healthcare Intelligence Platform, designed to help organizations unlock the full value of their data and accelerate AI-driven transformation. Innovaccer Gravity ™ seamlessly integrates healthcare enterprise data, enables cross-domain intelligence, and delivers faster return on investment (ROI), all while reducing total cost of ownership (TCO).
Built on a modern, cloud-agnostic architecture with enterprise-grade security and compliance (HIPAA, HITRUST), Innovaccer Gravity ™ unifies data from electronic health records (EHRs), claims, financial, operational, supply chain, HR and other core systems into a single source of truth. The platform's healthcare-native design, with 400+ pre-built connectors and 100+ FHIR resources, enables interoperability across clinical, operational, and financial domains, empowering leaders to drive better patient care, streamline operations, and improve financial performance.
'Health systems are under unprecedented pressure to do more with less, from improving outcomes to optimizing operations, all while managing rising costs,' said Abhinav Shashank, cofounder and CEO of Innovaccer. 'Gravity is purpose-built to address these challenges. It unifies data, scales AI adoption, and activates real-time insights, enabling healthcare organizations to drive meaningful change, faster and more cost-effectively.'
Key capabilities of Innovaccer Gravity ™ include:
Unified Data Fabric: Integrates clinical, operational, and financial data into a single, trusted foundation with real-time alerts and actionable insights.
AI-First Enterprise Intelligence Layer: Leverages Innovaccer's AI framework to provide pre-built foundational AI models (text-to-speech, speech-to-text, OCR, speech analytics) built for healthcare and customizable AI/ML workbenches.
Low-Code/No-Code Self-Serve Tools: Empowers analysts, scientists, and developers to rapidly build and deploy agents, solutions using open APIs and self-service AI/ML capabilities.
Build and Extend with Your Own Data and AI: Enables organizations to bring their own data, build custom analytics, develop AI models, and create tailored applications on top of Innovaccer's rich content library and pre-built assets.
Enterprise-Grade Security & Governance: Ensures data integrity with built-in master data management, data governance, and cloud-agnostic scalability.
Accelerated Time-to-Value: Reduces deployment timelines from months to weeks, driving faster adoption of business-critical use cases.
Innovaccer Gravity ™ is designed for health system leaders, including CFOs, CIOs, CTOs, and CDOs, who are seeking to modernize legacy infrastructure, improve operational efficiency, and demonstrate tangible ROI on data initiatives.
With its future-proof architecture and healthcare-native intelligence, Gravity positions Innovaccer as the definitive platform for health systems seeking to accelerate digital transformation.
Innovaccer Gravity ™ beta is now available to health systems across the U.S, with general access in upcoming quarters.
For more information about Innovaccer Gravity ™, the Healthcare Intelligence Platform, visit get-gravity.ai.
About Innovaccer
Innovaccer activates the flow of healthcare data, empowering providers, payers, and government organizations to deliver intelligent and connected experiences that advance health outcomes. The Healthcare Intelligence Cloud equips every stakeholder in the patient journey to turn fragmented data into proactive, coordinated actions that elevate the quality of care and drive operational performance. Leading healthcare organizations like CommonSpirit Health, Atlantic Health, and Banner Health trust Innovaccer to integrate a system of intelligence into their existing infrastructure— extending the human touch in healthcare. For more information, visit www.innovaccer.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 hours ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
Business Wire
10 hours ago
- Business Wire
BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of BioSig Technologies, Inc. (NasdaqCM: BSGM) and Streamex Exchange Corporation. Upon closing of the proposed transaction, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to BioSig shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
11 hours ago
- Business Wire
SIGNING DAY SPORTS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Signing Day Sports, Inc.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of Signing Day Sports, Inc. (NYSE: SGN) and One Blockchain LLC. Upon closing of the proposed transaction, Signing Day shareholders are expected to own approximately 8.5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Signing Day shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
